REGENXBIO(US:RGNX) TMX Newsfile·2026-02-21 03:24Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of REGENXBIO, Inc. securities during the specified Class Period, indicating potential legal recourse for affected investors [1]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between February 9, 2022, and January 27, 2026, and aims to provide compensation to investors without any out-of-pocket fees through a contingency fee arrangement [2]. - Investors wishing to serve as lead plaintiffs must file their motion by April 14, 2026, to represent other class members in the litigation [1][3]. Group 2: Case Background - The lawsuit claims that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I (Hurler syndrome) [5]. - Defendants allegedly made positive assertions about RGX-111's trial success based on favorable biomarker and safety data while concealing material adverse facts about the trial's efficacy and safety [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4].